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Abstract
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL
might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international
multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome.
Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with
severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age
(≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent
(≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate
for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151
patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not
impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors)
appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and
immunodeficiency.
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Introduction
Coronavirus disease 2019 (COVID-19), the new pandemic
caused by coronavirus 2 (SARS-COV-2), has heavily
affected the population worldwide since first recognized in
December 2019 in Wuhan, China [1]. The disease follows
a very heterogenous course, where the vast majority of
patients are asymptomatic or experience few and mild
symptoms, while others experience a very aggressive clin-
ical course and progress rapidly to severe acute lung injury
and acute respiratory distress syndrome, often associated
with multiorgan failure (MOF) [2].
Evidence is gathering on the double-faceted role of the
immune system in SARS-CoV-2 infection. An intact immune
response is needed to face the initial infection and clear the
virus, with patients recovering from the infection demon-
strating evidence of humoral neutralizing antibodies [3].
On the other hand, the severity of COVID-19 and MOF
occurrence seem to be related to clinical and laboratory
parameters of inflammatory response (lymphopenia, hypoal-
buminemia, higher levels of alanine aminotransferase, lactate
dehydrogenase, C-reactive protein, ferritin, and D-dimer)
and markedly higher levels of proinflammatory cytokines
(interleukin-2 receptor, IL6, IL-10, and tumor necrosis factor-
α) [4]. On these grounds, therapies targeting inflammation
(e.g., IL6/IL6R antibodies or steroids) have been used and
shown potential benefit in full-blown COVID-19 patients [5].
Symptomatic disease and severe disease manifestations
are more prevalent in elderly and co‐morbid individuals [6].
The role of concomitant cancer, particularly for hematologic
malignancies, remains unclear [7–10], with initial evidence
suggesting an increased risk of infection and of experien-
cing a rapid disease course in patients with cancer [6].
Studies from China have reported a statistically higher
incidence of severe events (including intensive care unit
admission/ventilation/death) in infected individuals with
cancer compared to those without. Moreover, in a recent
series focused on patients with hematologic neoplasms
hospitalized for COVID-19, those without active cancer
(watch & wait strategy and remission status) presented a
favorable outcome [11]. In that cohort, six out of six
patients diagnosed with chronic lymphocytic leukemia
(CLL) survived the infection [11]. A similarly favorable
outcome was reported in a Spanish cohort focusing on
patients with CLL, where all four affected cases recovered
from COVID-19 without intensive care admission [12].
Besides this report, only anecdotal CLL cases have been
reported so far [13].
CLL is a paradigmatic example of malignancy associated
with impaired immune responses to common pathogens in a
context of a profound immune dysregulation reflected by
hypogammaglobulinemia, qualitative and quantitative B- and
T-cell defects, including impaired response to vaccination,
and CD4+ lymphopenia, as well innate immune dysfunction
and neutropenia [14, 15]. This can be further exacerbated by
antileukemic treatments that by definition impact on the host
immune system, some applied continuously until progression
[16]. This could arguably compromise the capacity of patients
with CLL to clear the virus, with a possible higher infection
risk for this population. Conversely, immunodeficiency
might as well be protective against severe COVID-19 and
MOF, limiting excessive activation of the immune system. In
this context, the role of novel targeted therapies such as
Bruton tyrosine kinase (BTK) inhibitors, with overall anti-
inflammatory activity due to effects on both innate immune
cells and platelets, has also been proposed as potentially
beneficial against severe disease manifestations [17]. Never-
theless, patients with CLL tend to be elderly and carry several
comorbidities, representing, in principle, prototypic patients
who may suffer the most severe consequences of a SARS-
CoV-2 infection.
Limited data are currently available on the clinical course
of COVID-19 patients with CLL and the potential impact of
antileukemic treatment on the severity and outcome of
COVID-19. Thus, we undertook this retrospective interna-
tional multicenter study in order to characterize the course
of COVID-19 in patients with CLL and identify potential
predictors of outcome.
Materials and methods
Data collection
This is a retrospective international multicenter study of the
European Research Initiative on CLL (ERIC) and the CLL
Campus. Participating members received a survey during
the COVID-19 pandemic, using a cloud-based online
platform. Investigators who confirmed patients with CLL
and COVID-19 in their patient cohort were asked to fill a
template with relevant clinical information. The study was
approved by the institutional ethics committee, informed
consent was obtained from all subjects. Data collection
took place between March 28 and May 22, 2020. The full
list of participating countries is reported in Supplementary
Table 1.
Data extracted from the medical records included:
baseline demographics, date of CLL diagnosis, CLL treat-
ment status, presence, number, and type of comorbidities,
date of COVID-19, COVID-19 symptoms, COVID-19
management, treatment, and outcome. Of the 190 patients
studied, four Spanish cases were previously published
in extenso [12], 47 patients were included in a report
describing the impact of SARS-CoV-2 pandemic infection
on the practical management of CLL in Italy with only
limited clinical data [18].
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Overall survival (OS) was defined as the time from
suspected COVID-19 to death or last follow-up date.
In keeping with international practice, patients were
deemed to have COVID-19 if an RT-PCR assay test from a
throat or nose swab was positive for SARS-CoV-2. Patients
with only radiological or clinical suspicion of COVID-19
yet testing negative by RT-PCR were not further analyzed.
Establishment of CLL diagnosis, treatment decisions,
review of medical history, and assessment of patient status
were performed by the local teams following international
guidelines [19].
Severe COVID-19 was defined as hospitalization and
need of oxygen or admission into an intensive care unit;
nonsevere/mild COVID-19 was defined as confinement at
home or hospitalization without need of oxygen. Hospita-
lized patients were defined as those with severe COVID-19
and those requiring hospitalization without need of oxygen.
Statistical analysis
Subgroups analyses were performed, stratifying patients
based on (1) clinico-biological characteristics (age, comor-
bidities, gender); (2) severity of COVID-19 (severe vs
nonsevere); (3) antileukemic treatment (ongoing or previous
last therapy within the last 12 months vs never treated or
previous last therapy > 12 months, considering that therapy-
related immunosuppresion after chemoimmunotherapy
(CIT) may persist in the first year after discontinuation).
Subgroup analyses of patients with severe COVID-19 were
carried out to better identify risk in this cohort of patients:
these analyses stratified between untreated vs treated
patients; and, those on treatment or recently treated vs never
treated or off treatment for >12 months.
Means between groups were compared using indepen-
dent group t-test and the Mann–Whitney test for normally
and abnormally distributed data, respectively. Proportions
for categorical variables were compared by chi-square or
Fisher’s test when appropriate. Survival outcomes were
analyzed according to the Kaplan–Meier estimator. The
analysis was performed using IBM SPSS version 26.0,
Microsoft Excel Office 365, and Graphpad Prism v8.4.2.
Results
Survey results
One-hundred and twenty-one investigators from 118 sites
completed the survey; most participants were hematologists.
Among 121 responders, 58 confirmed the presence of
COVID-19 cases in their CLL patient cohort. Most
responders were from Europe (74.6%), followed by Asia
(13.6%), Latin America (4.2%), Africa (3.4%), Canada
(2.5%), and Australia (1.7%). At the time of launching the
data collection, we became aware of ongoing US colla-
borative initiatives on the same topic; therefore, in order to
avoid potential redundancy, US sites were intentionally
excluded from our survey.
All sites participating in the survey except one (0.8%)
reported implementing preventive measures for patients
with CLL regarding the SARS-CoV-2 pandemic, applied to
all patients with CLL (57.0%) or only those attending the
clinic (43.0%). In the vast majority of cases (105/118 sites)
these measures were implemented according to national
recommendations for the SARS-CoV-2 pandemic. The
main actions taken included frequent hand washing and
wearing masks and gloves for health care professionals,
sanitizers at the entrance of the visiting room, postponing
visits, and implementing remote visit platforms. The full list
of measures is reported in Supplementary Table 2.
COVID-19 cases: site and patient disposition
Among 221 cases with suspected COVID-19 based on
presenting symptoms and/or imaging findings, 206 under-
went molecular testing (RT-PCR) on nasopharyngeal swabs
for SARS-CoV-2; of these, 190 (92.2%) tested positive by
RT-PCR and were selected as the study cohort.
Information on the total number of patients followed at
each site was available for 47 participating sites, con-
tributing 82.1% of all COVID-19 patients with CLL in our
series. Collectively, these sites reported 156 COVID-19
cases among 15,083 (1.0%) patients with CLL attended at
the respective institutions. The proportion of patients
developing symptomatic COVID-19 requiring hospitaliza-
tion was 141/15,083 (0.9%).
Patient characteristics, including CLL and treatment
status at the time of COVID-19, are shown in Table 1.
Median age at COVID-19 diagnosis was 72 years (range
48–94), with the expected male: female ratio of 2.0. At the
time of COVID-19, 76% of patients (145/190) carried one
or more comorbidities, with a median number of 2 (range
1–9): the most frequent concerned hypertension (78 cases,
54%), cardiovascular diseases (42 cases, 29%), diabetes
mellitus (35 cases, 24%), chronic obstructive pulmonary
disease (COPD, 9 cases, 6%), other respiratory diseases
(21, 14%), other malignancies (18, 12%).
Regarding CLL history, 73 (38.4%) patients were
previously untreated, whereas 116 (61.1%) had previously
received and/or were receiving treatment for CLL (miss-
ing information: 1 patient). Number of lines of treatment
were: 1 in 62, 2 in 30, 3 in 15, 4 in 6, >4 in 3 patients.
Sixty-five patients (34.2%) were receiving treatment for
CLL at the time of COVID-19 diagnosis: 44 were on a
BTK inhibitor (ibrutinib 39, acalabrutinib 4, zanubrutinib
1), 9 on venetoclax-based regimens, 3 on idelalisib, 3
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on chlorambucil ± obinutuzumab, 2 on bendamustine+
rituximab (BR), and 4 on other regimens (steroids and/or
chemotherapy, mainly for autoimmune complications).
Another 51 patients (26.8%) had been previously treated
but were not receiving treatment at the time of COVID-19
diagnosis. Amongst these, 19 (37.3%) had received
the following therapies in the previous 12 months:
fludarabine, cyclophosphamide, and rituximab (FCR, 5),
BR (4), other CITs (4), allotransplant (1), novel agents
[ibrutinib (3), venetoclax (1), idelalisib+ rituximab (1);
no available information regarding treatment cessation].
Thirty-two of 51 patients (62.7%) had been treated >1
year prior to COVID-19 with the following regimens:
FCR (10), BR (3), ibrutinib ± rituximab (4), venetoclax
(1), other CITs (13), experimental agents (1). Overall,
the median time between the last line of treatment and
COVID-19 was 20 months (range 13 months to 10 years).
Eighty-nine of 154 patients (57.8%) for whom this infor-
mation was available had documented hypogammaglobuli-
nemia at the time of COVID-19.
Detailed information about the comorbidity and treat-
ment profiles of the studied patients is given in Supple-
mentary material and Supplementary Table 3.
COVID-19 manifestations and management
Patients with CLL and COVID-19 presented with fever
(165/190, 87%) and respiratory symptoms, including
cough (93/190, 49%) and dyspnea (92/190, 48%). Other
common manifestations included fatigue (32/190, 17%),
diarrhea (22/190, 12%), myalgias/arthralgias (19/190,
10%), headache (13/190, 7%), while anosmia/ageusia
(5/190, 3%), nausea and vomiting (5/190, 3%), and
abdominal pain (3/190, 2%) were rare (Table 2).
Twenty-one of 190 patients (11.1%) were managed at
home, while 169 (88.9%) required hospitalization, in 112/
169 with need of oxygen supplementation, 39 in the
intensive care unit. Most patients (168/187, information
missing only in 3 cases) received at least 1 pharmacologic
treatment for COVID-19, including: hydroxychloroquine
or similar (76%), antivirals (50%), azithromycin (47%),
anti-IL6 and/or anti-IL6R monoclonal antibodies (23%)
(Table 2).
Among 65 patients receiving treatment for CLL at the
time of COVID-19, 54 (83%) stopped treatment (acalab-
rutinib 4/4, ibrutinib 30/39, zanubrutinib 1/1, idelalisib 2/3,
venetoclax ± rituximab 9/9, CIT, and/or steroids 8/9).
Among those who continued treatment as planned, nine
were on ibrutinib, one on idelalisib and one was receiving
steroid treatment due to autoimmune hemolytic anemia.
Of 45 patients with severe COVID-19 under CLL-specific
treatment, 31 were receiving BTK inhibitors: the infection
outcome in these 31 patients was resolution (14), still
unresolved (4), death (13). In 13 patients with less severe
COVID-19 on BTK inhibitors, the outcome was resolution
(7), still unresolved (4) and death (1), with 1 missing.
After a median follow-up of 23 days (range 2–86), 96
patients completely recovered (median time to recovery
22.5 days, range 2–86), 37 were still under medical care and
56 died; infection outcome was missing only in 1 case
Table 1 Patients’ characteristics.
Characteristic Result
Median age, years (range, years) 72 (48–94)
Male/female 126/64
Diagnosis
CLL|MBL (%) 183/2 (96)
SLL (%) 5 (3)
Patients with comorbidities at the time of
COVID-19 (%)
145 (76)
Median number of comorbidities (range) 2 (1–9)
Median time between CLL diagnosis and
COVID-19, months (range, months)
81 (0–30 years)
Type of comorbidities
Hypertension (%) 78 (54)
Diabetes mellitus (%) 35 (24)
COPD (%) 9 (6)
Cardiovascular (%) 42 (29)
Respiratory (%) 21 (14)
Other malignancies (%) 18 (12)
CLL treatment history
Previously untreated (%) 73 (38.6)
Received treatment (%) 116 (61.4)
1 line of treatment 62
2 lines of treatment 30
3 lines of treatment 15
4 lines of treatment 6
>4 lines of treatment 3
Missing information 1
On treatment at the time of COVID-19 (%) 65 (34.2%)
BTK inhibitor (acalabrutinib, ibrutinib,
zanubrutinib) (%)
44 (67.7)
Venetoclax-based regimens (%) 9 (13.8)
Idelalisib (%) 3 (4.6)
Chlorambucil ± obinutuzumab (%) 3 (4.6)
Bendamustine+ rituximab (%) 2 (3.1)
Other (chemotherapy ± steroids) (%) 4 (6.2%)
Hypogammaglobulinemia
Present (%) 89 (57.8)
Absent (%) 65 (42.2)
Missing information 36
CLL chronic lymphocytic leukemia, SLL small lymphocytic lym-
phoma, MBL monoclonal B-cell lymphocytosis, COPD chronic
obstructive pulmonary disease, BTK Bruton tyrosine kinase.
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(Table 2). Median OS was not reached, with 69% of
patients alive at 30 days (Fig. 1).
Predictors of outcome of COVID-19 in CLL
Comparisons between 151 patients who required hospitali-
zation with oxygen support and/or were admitted to the
intensive care unit, thus experiencing severe COVID-19,
versus 39 patients confined at home and/or requiring hos-
pitalization without need of oxygen, therefore, considered to
have a less severe infection course, revealed no differences
regarding gender, the presence of three or more comorbid-
ities or hypogammaglobulinemia (Table 3).
In contrast, these comparisons revealed significant dif-
ferences regarding age, CLL treatment history and mortal-
ity. In particular, 112/151 (74.2%) in the severe group were
≥65 years compared to only 17/39 (43.6%) in the less severe
group (p < 0.05). Moreover, significantly (p < 0.05) more
patients (91/151, 60.3%) in the severe COVID-19 group
were off treatment within the last year or had never received
treatment for CLL compared to less severe cases (15/39,
38.5%). In addition, hospitalization rate due to COVID-19
was significantly different depending on the type of
treatment. In particular, 27/1729 (1.6%) on ibrutinib were
Fig. 1 Overall survival in our patient cohort (n= 190). Overall
survival of patients with CLL and COVID-19 in days from suspected
COVID-19 until last follow-up.
Table 3 Patients’ disposition based on COVID-19 severity.
Variable Severe
COVID-19
(n= 151)
Nonsevere
COVID-19
(n= 39)
p
Age
≥65 years (%) 112 (74.2) 17 (43.6) <0.05
<65 years (%) 39 (25.8) 22 (56.4)
Gender
Male (%) 98 (64.9) 28 (71.8) n.s.
Female (%) 53 (35.1) 11 (28.2)
Median time between
CLL diagnosis and
COVID-19
88 71 n.s.
Treatment for CLL
Untreated (%) 64 (42.7) 9 (23.1) <0.05
Treated (%) 86 (57.3) 30 (76.9)
Treatment during the last 12 months or ongoing
Yes (%) 60 (39.7) 24 (61.5) <0.05
Untreated or treated >
12 months before (%)
91 (60.3) 15 (38.5)
Treatment
1 previous line (%) 48 (31.8) 14 (35.9) n.s.
2 or more previous
lines (%)
38 (25.2) 16 (41.0)
Comorbidities
>2 46 (30.5) 12 (30.8) n.s.
≤2 105 (69.5) 27 (69.2)
Hypogammalobulinemia
Yes 66 (55.0) 23 (67.6) n.s.
No 54 (45.0) 11 (32.4)
Outcome
Alive (%) 96 (63.6) 37 (97.4) <0.00001
Dead (%) 55 (36.4) 1 (2.6)
Bold values indicate statistical significance p < 0.05.
Table 2 Clinical presentation and management of patients with
COVID-19.
Characteristic Result
Symptoms No (%)
Fever 165 (87)
Cough 93 (49)
Dyspnea 92 (48)
Myalgias/arthralgias 29 (15)
Nausea and vomiting 5 (3)
Diarrhea 22 (12)
Fatigue 32 (17)
Anosmia/ageusia 5 (3)
Nasal discharge 5 (3)
Sore throat 8 (4)
Abdominal pain 5 (3)
Management of COVID-19
Confinement at home 21 (11)
Hospitalization without need of oxygen 18 (10)
Hospitalization with need of oxygen 112 (59)
Intensive care 39 (20)
Pharmacological treatment for COVID-19
Antivirals 95 (50)
Hydroxychloroquine or similar 145 (76)
Azithromycin 90 (47)
Monoclonal antibodies against IL6/IL6R 43 (23)
COVID-19 outcome
Resolution 96 (51)
Still under medical care 37 (19)
Death 56 (30)
Missing 1
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hospitalized because of COVID-19, 8/442 (1.8%) on
venetoclax and 18/428 (4.2%) on CIT with a higher risk in
those treated with CIT compared to ibrutinib (odds ratio
(OR) 2.77, 95% CI 1.51–5.10, p < 0.01) and venetoclax
(OR 2.77, 95% CI 1.02–5.54, p < 0.05). Moreover, hospi-
talization rate for severe COVID-19 was lower for those on
ibrutinib (OR 0.44 [95% CI 0.20–0.96] p < 0.05) as com-
pared to those receiving any other CLL-specific treatment or
off treatment.
The disposition of patients who died because of COVID-
19 is reported in Table 4. Unsurprisingly, the death rate was
significantly (p < 0.00001) higher in severe (55/151, 36.4%)
versus less severe COVID-19 cases (1/38 cases with
available data; 2.6%). Of note, however, amongst those who
died because of severe COVID-19, age was not found to
associate with mortality risk [16/61 patients (26.2%) <65
years died versus 40/129 (31%) patients ≥65 years; p=
non significant].
Discussion
To the best of our knowledge, we present here the largest
European series of patients with CLL infected by SARS-
CoV-2 and experiencing COVID-19. Among the European
cases (96.8% of the total) included in this project, almost
90% originate from Italy and Spain, hence mirroring the
dynamics of the SARS-CoV-2 pandemic in Europe with
Italy being the first country in number of infected indivi-
duals followed by Spain, with a lower incidence, e.g., in
Greece or Northern countries.
Patients were strictly selected and included in this ret-
rospective analysis only if they had a confirmed COVID-19
diagnosis by molecular testing and were followed at the
participating sites. In order to avoid the possibility of
ascertainment biases due to the fact that in most countries
only patients with relevant symptoms are tested for SARS-
CoV-2, we tried to draw conclusions in particular from
cases requiring hospitalization with or without oxygen
support and/or intensive care admission, making it more
comparable in all different national situations.
In line with previous reports in the general population,
also in our cohort older age was associated with more
severe COVID-19 manifestations: in particular, the group of
patients admitted to the hospital requiring oxygen and/or
ventilatory support was enriched for patients ≥65 years
compared to those with milder disease. The presence of
three or more comorbidities was not significantly different
in patients hospitalized with severe versus nonsevere dis-
ease; moreover, the presence of hypogammaglobulinemia, a
frequent laboratory finding in CLL, did not show a relevant
impact on the clinical course of COVID-19 patients, prob-
ably underscoring the relevance of the inflammatory
Table 4 Characteristics of CLL patients who died of COVID-19
(n= 56).
Characteristic Result
Median age, years (range, years) 75.5 (51–91)
Male/female 38/18
Diagnosis
CLL (%) 54 (96.4)
SLL (%) 1 (1.8)
MBL (%) 1 (1.8)
Patients with comorbidities at the time of COVID-
19 (%)
46 (82.1)
Median number of comorbidities (range) 2 (1–9)
Type of comorbidities
Hypertension (%) 26 (46.4)
Diabetes mellitus (%) 10 (17.9)
COPD (%) 4 (7.1)
Cardiovascular (%) 10 (17.9)
Respiratory (%) 6 (10.7)
Other malignancies (%) 4 (7.1)
CLL treatment history
Previously untreated (%) 18 (32)
Received treatment (%) 38 (68)
1 line of treatment 21
2 lines of treatment 8
3 lines of treatment 5
4 lines of treatment 3
>4 lines of treatment 1
On treatment at the time of COVID-19 (%) 19 (34)
BTK inhibitor (acalabrutinib, ibrutinib) 12
Venetoclax-based regimens 1
Idelalisib 1
Chemoimmunotherapy 3
Corticosteroids 1
Other (chemotherapy ± steroids) 1
Hypogammaglobulinemia
Present (%) 32 (64)
Absent (%) 18 (36)
Missing information 6
Pharmacological treatment for COVID-19
Antivirals (%) 30 (54)
Hydroxychloroquine or similar (%) 38 (68)
Azithromycin (%) 18 (32)
Monoclonal antibodies against IL6/IL6R (%) 9 (16)
Management
Confinement at home 1 (1.8)
Hospitalization without need of oxygen 0
Hospitalization with need of oxygen 39 (69.6)
Intensive care 16 (28.6)
CLL chronic lymphocytic leukemia, SLL small lymphocytic lymphoma,
MBL monoclonal B-cell lymphocytosis, COPD chronic obstructive
pulmonary disease, BTK Bruton tyrosine kinase.
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reaction rather than the viral replication (and the capacity to
clear it by antibody-mediated immune response) in shaping
the severity of the disease.
The potential impact of CLL-specific treatments on the
course of COVID-19 still needs to be fully elucidated, with
international guidelines suggesting careful evaluation of
pros/cons of treatment interruption, in particular in patients
on targeted agents [20]. Taking into consideration the
potential long-term effect on the immune system and the
risk of infections (up to 12 months) particularly for patients
treated with CIT, we grouped together patients who were on
ongoing or had received recent (<12 months) therapies vs
patients with no treatments in their lifetime or in the past
previous year. Relevant to mention in this respect, our
cohort of COVID-19 patients is enriched for patients
receiving treatment for CLL compared to a standard
population (indeed 2679/15,083, 17.8% were on treatment
at participating sites, while 65/190, 34.2% COVID-19 cases
were treated). Interestingly, patients under ibrutinib less
likely needed hospitalization suggesting a diverse effect of
the antileukemic treatments, probably due to a different
impact on the immune deficiency and/or dysregulation.
Along the same direction, we here report that patients on
recent or ongoing treatment were more likely to have a
milder COVID-19 compared to those with severe disease
who in the vast majority were on a watch and wait follow-
up. It is important to note that a relevant proportion of
patients included into the study were on BTK inhibitors but,
due to limited numbers of patients treated with other
therapies, our study does not allow reaching firm conclu-
sions on potential differences between the different types of
treatment (BTK inhibitors vs venetoclax-based regimens vs
CIT and/or steroids). Altogether, these data seem to further
underscore the possible protective role of specific targeted
therapies against a dismal evolution of the SARS-CoV-2
infection [17, 21].
Considering the median age of 72 years at the time of
COVID-19 occurrence and the presence of at least one
comorbidity in ~75% of our patients (median number of
comorbidities 2), the high mortality rate (55/169, 32.5%)
among the hospitalized patients reported in this cohort
comes as no surprise, though it is apparently higher than
expected in the general population (e.g., 13.4% amongst the
general population in Italy) (https://www.epicentro.iss.it/
coronavirus/). However, if we consider only patients with
CLL ≥ 70 years of age, the percentage (36/105, 34.3%) is not
considerably different from that of normal individuals >70
years (25.5%, https://www.epicentro.iss.it/coronavirus/)
[18]. The difference in the overall mortality rate was seen in
all age groups, with young patients (<65 years) succumbing
to the disease at rates similar to those of the elderly (26.2%
and 31.0%, respectively), though the elderly patients were
more likely to experience severe COVID-19, as reported
above. This evidence is pointing to the fact that when severe
COVID-19 occurs, it is probably the underlying leukemic
disease with the typical immune dysregulation that predis-
poses to a dismal outcome, levelling off the death risk and
overcoming the effect of age and other comorbidities.
Along the same line of reasoning, the apparent higher
rate of hospitalization in our cohort (141/15,083, 0.9%)
compared to a much lower rate for example in the Italian
population (0.24%) (https://www.epicentro.iss.it/corona
virus/) may simply be due to older age and higher comor-
bidity burden of the patients with CLL here reported.
Our study has some limitations: (1) the large majority of
CLL cases was provided by only two countries (Italy and
Spain), making the case series possibly not fully repre-
sentative of the COVID-19 course in other countries; (2)
cases with more severe clinical presentations had a higher
probability of being included in the study due to having a
confirmed COVID-19 diagnosis, making it difficult to
define the prevalence, morbidity and mortality compared to
the general population, that indeed was the aim of our study.
To mitigate at least in part these limitations, we restricted
our analyses to hospitalized patients that are more objec-
tively recorded in all different national situations. Despite
these limitations, our series thoroughly describes COVID-
19 outcome in a large cohort of patients with CLL in Europe
and suggests that these patients may be at a higher risk
of developing symptomatic COVID-19 and of succumbing
to the disease due to the underlying leukemia, while at
least some CLL treatments may favorably influence
COVID-19 course. This finding warrants further investiga-
tion to understand the potential protective role of CLL
treatment, in particular with BTK inhibitors, on the clinical
course, morbidity and mortality of COVID-19 patients
with CLL.
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